DBV Technologies (DBVT) Receives Media Sentiment Score of 0.17
News stories about DBV Technologies (NASDAQ:DBVT) have trended somewhat positive on Wednesday, Accern Sentiment Analysis reports. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. DBV Technologies earned a daily sentiment score of 0.17 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.8870722958961 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
- DBV Technologies Stock Up On Positive Safety Results From Viaskin Peanut Trial (rttnews.com)
- SMMT To Report Data In Q1, PRTA Slumps, DBVT’s Viaskin Value Realised (nasdaq.com)
- DBV Technologies Announces Positive Topline Safety Results from REALISE Phase III Trial of Viaskin Peanut for the Treatment of Peanut-Allergic Patients (finance.yahoo.com)
- JMP Securities Begins Coverage on DBV Technologies S.A. (DBVT) (americanbankingnews.com)
A number of equities research analysts recently issued reports on the company. Leerink Swann set a $49.00 price objective on DBV Technologies and gave the stock an “outperform” rating in a research report on Monday, October 23rd. Morgan Stanley downgraded DBV Technologies from an “overweight” rating to an “equal weight” rating in a research report on Monday, October 23rd. HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of DBV Technologies in a research report on Monday, October 23rd. Barclays PLC lowered their price objective on DBV Technologies from $58.00 to $30.00 and set an “overweight” rating on the stock in a research report on Monday, October 23rd. Finally, Deutsche Bank AG increased their price objective on DBV Technologies from $46.00 to $56.00 in a research report on Sunday, October 8th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have given a buy rating to the stock. DBV Technologies currently has a consensus rating of “Buy” and an average target price of $49.63.
DBV Technologies (NASDAQ:DBVT) traded up $0.28 during midday trading on Wednesday, reaching $24.70. The company’s stock had a trading volume of 145,315 shares, compared to its average volume of 224,850. DBV Technologies has a twelve month low of $21.51 and a twelve month high of $50.57.
DBV Technologies Company Profile
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with Analyst Ratings Network's FREE daily email newsletter.